{
    "nctId": "NCT06535893",
    "briefTitle": "Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer",
    "officialTitle": "Sustainable and Efficient Platform of New Therapeutic Development for Early Breast Cancer (S-FACT)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "pathological complete response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically or cytologically confirmed invasive breast carcinoma\n2. Stage II or III\n3. ECOG performance status of 0 or 1\n4. Age 18-80\n\nExclusion Criteria:\n\n1. Continuous systemic administration (oral or intravenous) of steroid drugs or other immunosuppressants.\n2. History or complication of interstitial lung disease or pulmonary fibrosis diagnosed by imaging or clinical findings.\n3. Infection requiring systemic treatment.\n4. Active double cancer (however, the following are not excluded: (1) Completely resected cancers: basal cell carcinoma, squamous cell carcinoma at clinical stage I, carcinoma in situ, mucosal carcinoma, superficial bladder carcinoma, (2) Gastrointestinal cancer that has been curatively resected by ESD or EMR, (3) Other cancers that have not recurred for more than 5 years).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}